Hemoperfusion Efferon СT for the Extremely Severe Form of COVID-19 - Trial NCT06402279
Access comprehensive clinical trial information for NCT06402279 through Pure Global AI's free database. This phase not specified trial is sponsored by Efferon JSC and is currently Completed. The study focuses on COVID-19. Target enrollment is 130 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Efferon JSC
Timeline & Enrollment
N/A
Oct 01, 2020
Dec 01, 2023
Primary Outcome
Effect of Efferon CT hemoperfusion on Ventilator-free days (VFDs)
Summary
The development of acute respiratory and renal failure of COVID-19 patients is associated
 with an excessive immune response and hyperproduction of anti-inflammatory cytokines, which
 leads to impaired endothelial function and a dysregulated balance between the coagulation and
 fibrinolytic systems in the blood. These factors contribute to the development of multi-organ
 failure, sepsis, and high mortality rates.In the absence of effective etiotropic therapy for
 COVID-19, it is necessary to search for alternative, pathogenetically based treatment
 approaches, including extracorporeal methods of homeostasis support. This observational study
 examines the effect of early hemoperfusion using the Efferon CT device for the treatment of
 patients with severe forms of COVID-19 after their intubation on a ventilator.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06402279
Device Trial